Biomind Labs Inc.
BMNDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.14 | 0.10 | 0.27 | -0.09 |
| FCF Yield | -1.51% | -10.24% | -7.86% | -2.81% |
| EV / EBITDA | -60.93 | -7.91 | -9.46 | -22.03 |
| Quality | ||||
| ROIC | 62.83% | 140.12% | 1,207.12% | -149.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.36 | 0.63 | 0.72 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 53.73% | 64.39% | 0.75% | -1,343.59% |
| Safety | ||||
| Net Debt / EBITDA | -1.70 | -0.69 | 0.01 | 0.66 |
| Interest Coverage | -12.73 | -5.94 | -2,211.94 | -923.64 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19,220.08 | -13,281.44 | 0.00 | -3,766.02 |